Innoviva (INVA) Equity Income (2022 - 2026)
Innoviva posted quarterly Equity Income of $157.6 million for Q1 2026, up 1263.55% year-on-year from $11.6 million in Q1 2025, and up 412.67% on a QoQ basis from $30.8 million in Q3 2025.
Innoviva (INVA) has 5 years of Equity Income data on file, last reported at $157.6 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Income rose 1263.55% year-over-year to $157.6 million; the trailing twelve-month figure through Mar 2026 stood at $187.9 million (up 432.36% YoY), and the FY2025 full-year result was $141.4 million, up 320.12% from the prior year.
- Equity Income for Q1 2026 stood at $157.6 million, up from $30.8 million in the prior quarter.
- Across five years, Equity Income topped out at $157.6 million in Q1 2026 and bottomed at -$60.1 million in Q2 2024.
- The 5-year median for Equity Income is $10.3 million (2022), against an average of $12.9 million.
- The widest annual swing landed in 2024, when Equity Income slumped 201.88%; it then surged 1263.55% in 2026.
- A 5-year view of Equity Income shows it stood at $10.3 million in 2022, then jumped by 598.97% to $72.0 million in 2023, then tumbled by 125.33% to -$18.2 million in 2024, then surged by 268.67% to $30.8 million in 2025, then soared by 412.67% to $157.6 million in 2026.
- The last three Equity Income figures came in at $157.6 million (Q1 2026), $30.8 million (Q3 2025), and $13.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 157.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.65 Mn |
| Sep 30, 2025 | 30.75 Mn |
| Jun 30, 2025 | 13.08 Mn |
| Mar 31, 2025 | -13.55 Mn |
| Sep 30, 2024 | -18.23 Mn |
| Jun 30, 2024 | -60.11 Mn |
| Mar 31, 2024 | 35.34 Mn |
| Sep 30, 2023 | 71.98 Mn |
| Jun 30, 2023 | -19.91 Mn |
| Mar 31, 2023 | 15.82 Mn |
| Sep 30, 2022 | 10.30 Mn |
| Jun 30, 2022 | -42.82 Mn |
| Mar 31, 2022 | -11.95 Mn |